Search results for "jak2"

showing 2 items of 12 documents

Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.

2009

A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis. The latter harbors the JAK2-V617F mutation and was treated with hydroxyurea and anagrelide. A bone marrow trephine biopsy disclosed 2 morphologically distinct areas of chronic primary myelofibrosis and acute erythroleukemia. Microdissection and a separate molecular pathological analysis was performed. Although the activating JAK2-V617F mutation was not maintained in blasts of acute erythroleukemia, it was detectable in the chronic phase of primary myelofibrosis, indicating that this mutation did not play a role in the leukemic transformation of erythroid cells.

business.industryWild typeHematologyGeneral MedicineAnagrelideJanus Kinase 2Middle Agedmedicine.diseaseCell Transformation NeoplasticFatal OutcomePrimary Myelofibrosishemic and lymphatic diseasesMutation (genetic algorithm)Female patientCancer researchMedicineAcute erythroleukemiaHumansFemaleLeukemia Erythroblastic AcutebusinessMyelofibrosisJAK2 V617Fmedicine.drugActa haematologica
researchProduct

Diagnosis of exon 12‐positive polycythemia vera rescued by NGS

2020

Abstract A JAK2V617F‐negative polycythemia associated with low serum epo needs to be tested for an exon 12 JAK2 mutation. When negative, due to potential serious complications in PV, a next generation sequencing is necessary to rule out false negative results.

lcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematologyDNA sequencing03 medical and health sciencesExon0302 clinical medicinePolycythemia veraExon 12polycythemia verahemic and lymphatic diseasesmedicineerythrocytosisnext generation sequencinglcsh:R5-920business.industryJak2 mutationlcsh:RGeneral Medicinemedicine.diseaseVirologyJAK2030220 oncology & carcinogenesisbusinesslcsh:Medicine (General)Clinical Case Reports
researchProduct